A subsidiary of Sinopep Biotech (stock code 688076) focusing on difficult oligonucleotides, small molecules, and peptide manufacturing, providing services from preclinical research to commercial manufacturing. Relying on the company's 13 years of successful experience in process development services for small molecules, to peptides and oligonucleotide manufacturing from preclinical development to commercialization. Utilizing Norteno and oligonucleotide technology platform we can provide customers with GMP production services from preclinical sample preparation to oligonucleotide APIs and preparations that meet domestic and foreign regulatory requirements. Our process, analysis, formulation and regulatory teams provides customers with a fast, efficient, professional and flexible integrated solution for the entire oligonucleotide development process The Apextide's oligonucleotide & peptide platforms are equipped with the most advanced international CYTIVA equipment to provide a "one-stop" manufacturing service from laboratory research and development, process development to clinical stage scale-up production to commercialization, laboratory scale (gram level), pilot scale to commercial production scale (100 grams to kilogram level). Utilizing QHPLC/UPLC, LC-MS, LC-MS/MS, IC, GC, GC-MS, ICP-MS and other analytical facilities, which provide guarantee for oligonucleotide, peptide and small molecule structure characterization, analytical method development and verification, GMP production control and final product release testing, & stability research.